Recently, a liquid biopsy based medical test that detects several clinically significant EGFR somatic tumor mutations in the plasma of non-small cell lung cancer (NSCLC) patients has been approved by the FDA (16). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.